Generic Name and Formulations:
Estradiol 0.045mg + levonorgestrel 0.015mg; per day; transdermal system.
Company:
Bayer Healthcare Pharmaceuticals Inc.
Moderate to severe vasomotor symptoms of menopause in women with an intact uterus. Postmenopausal osteoporosis prevention.
Apply 1 patch once weekly to lower abdomen (avoid waistline); rotate application sites.
Not applicable.
Estrogen + progestin.
Undiagnosed abnormal genital bleeding. Thromboembolic disorders. Thrombophlebitis. Breast or estrogen-dependent carcinoma. Pregnancy (Cat.X).
Familial hyperlipoproteinemia or history of breast cancer. Hepatic insufficiency. Conditions aggravated by fluid retention. Endometriosis. Gallbladder disease. Bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include Pap smear, mammogram, and BP). Discontinue if visual abnormalities, hypertension or jaundice occurs and during immobilization, or at least 2 weeks before surgery associated with increased risk of thromboembolism. May interfere with lab tests (see literature). Nursing mothers.
See literature. May increase risk of breast cancer, gallbladder disease, thromboembolic disorders, others. Local irritation, fluid retention, breakthrough bleeding, mastodynia, nausea, abdominal cramps, headache, dizziness, intolerance to contact lenses.
Patches—4